97
Participants
Start Date
February 26, 2015
Primary Completion Date
August 25, 2021
Study Completion Date
July 9, 2024
Gilteritinib
Once-daily oral administration on 14 consecutive days in every cycle in each period.
Idarubicin
Induction period: Once-daily intravenous injection of 12 mg/m\^2 idarubicin on 3 consecutive days.
Cytarabine
"Induction period: Once-daily intravenous injection of 100 mg/m\^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m\^2 cytarabine on Days 1, 3, and 5."
Site JP81037, Anjo
Site JP00003, Nagoya
Site JP81003, Nagoya
Site JP81027, Nagoya
Site JP81038, Toyohashi
Site JP81010, Narita
Site JP81039, Matsuyama
Site JP81007, Yoshida-gun
Site JP00002, Maebashi
Site JP81001, Maebashi
Site JP81026, Fukuyama
Site JP81018, Ōtake
Site JP81014, Sapporo
Site JP81015, Sapporo
Site JP81043, Himeji
Site JP00007, Kobe
Site JP81006, Kobe
Site JP81036, Mito
Site JP81023, Tsukuba
Site JP81020, Kanazawa
Site JP81013, Isehara
Site JP00006, Yokohama
Site JP81005, Yokohama
Site JP81024, Yokohama
Site JP81035, Sendai
SIte JP81011, Ōmura
Site JP81041, Tenri
Site JP81022, Shimono
Site JP81040, Bunkyo-ku
Site JP00005, Shinagawa-ku
Site JP81032, Shinagawa-ku
Site JP81029, Akita
Site JP81008, Chiba
Site JP00001, Fukuoka
Site JP81004, Fukuoka
Site JP81025, Fukuoka
Site JP81031, Fukushima
Site JP81030, Gifu
Site JP81033, Kochi
Site JP81028, Kumamoto
Site JP81016, Kyoto
Site JP81012, Nagasaki
Site JP81009, Okayama
Site JP81019, Osaka
Site JP81021, Osaka
Site KR82005, Busan
Site KR82002, Incheon
Site KR82001, Seoul
Site KR82003, Seoul
Site KR82004, Seoul
Site KR82006, Seoul
Site TW88604, Kaohsiung City
Site TW88602, Taichung
Site TW88601, Tainan City
Site TW88603, Taoyuan District
Lead Sponsor
Astellas Pharma Inc
INDUSTRY